Roche runs short on Boniva after overestimating generic erosion
Many companies have been caught off-guard by the extent to which generic competition has eaten away at their sales. Genentech says it managed to be caught by surprise, however, by a lack thereof; leading to a shortage of the injectable version of its osteoporosis drug Boniva when demand outstripped its supply. Report
Like what you're reading?
Click here to get more news like this delivered to your inbox>>